NZ601232A - Tissue targeted antigenic activation of the immune response to treat cancers - Google Patents
Tissue targeted antigenic activation of the immune response to treat cancersInfo
- Publication number
- NZ601232A NZ601232A NZ601232A NZ60123207A NZ601232A NZ 601232 A NZ601232 A NZ 601232A NZ 601232 A NZ601232 A NZ 601232A NZ 60123207 A NZ60123207 A NZ 60123207A NZ 601232 A NZ601232 A NZ 601232A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tissue
- organ
- cancer
- compositions
- specific
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 230000000890 antigenic effect Effects 0.000 title abstract 3
- 230000004913 activation Effects 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 8
- 210000000056 organ Anatomy 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 244000000010 microbial pathogen Species 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of a treatment response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent visible delayed inflammatory immune reaction at the successive site or sites of administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ619899A NZ619899A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/553,972 US20070104733A1 (en) | 2004-06-07 | 2006-10-27 | Tissue targeted antigenic activation of the immune response to cancers |
| CA2571805A CA2571805C (en) | 2006-10-27 | 2006-12-20 | Tissue targeted antigenic activation of the immune response to cancers |
| NZ576590A NZ576590A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ601232A true NZ601232A (en) | 2014-01-31 |
Family
ID=39324077
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ576590A NZ576590A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ715882A NZ715882A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ601232A NZ601232A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ619899A NZ619899A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ576590A NZ576590A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
| NZ715882A NZ715882A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ619899A NZ619899A (en) | 2006-10-27 | 2007-10-25 | Tissue targeted antigenic activation of the immune response to treat cancers |
Country Status (2)
| Country | Link |
|---|---|
| NZ (4) | NZ576590A (en) |
| WO (1) | WO2008049231A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| SG187201A1 (en) * | 2010-07-26 | 2013-02-28 | Qu Biolog Inc | Immunogenic anti-inflammatory compositions |
| US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
| KR20140033309A (en) * | 2010-10-04 | 2014-03-18 | 브리티쉬 콜롬비아 캔써 에이전시 브랜치 | Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer |
| WO2015164979A1 (en) | 2014-05-02 | 2015-11-05 | Qu Biologics Inc. | Anti-microbial immunomodulation |
| CA3061077A1 (en) | 2016-04-26 | 2017-11-02 | Qu Biologics Inc. | Therapeutically triggering an innate immune response in a target tissue |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001056387A1 (en) * | 2000-02-01 | 2001-08-09 | Donnell Michael A O | Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen |
| DE60236318D1 (en) * | 2001-12-11 | 2010-06-17 | Pasteur Institut | PREPARATIONS OF GRAMPOSITIVE BACTERIA FOR THE TREATMENT OF DISEASES WITH IMMUNE RADIATION |
| WO2003063593A1 (en) * | 2002-01-28 | 2003-08-07 | Vion Pharmaceuticals, Inc. | Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent |
| PL1765391T3 (en) * | 2004-06-07 | 2013-08-30 | Qu Biologics Inc | Bacterial compositions for the treatment of cancer |
-
2007
- 2007-10-25 NZ NZ576590A patent/NZ576590A/en not_active IP Right Cessation
- 2007-10-25 NZ NZ715882A patent/NZ715882A/en unknown
- 2007-10-25 WO PCT/CA2007/001915 patent/WO2008049231A1/en active Application Filing
- 2007-10-25 NZ NZ601232A patent/NZ601232A/en not_active IP Right Cessation
- 2007-10-25 NZ NZ619899A patent/NZ619899A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ576590A (en) | 2012-08-31 |
| NZ715882A (en) | 2017-07-28 |
| WO2008049231A1 (en) | 2008-05-02 |
| NZ619899A (en) | 2016-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601232A (en) | Tissue targeted antigenic activation of the immune response to treat cancers | |
| MX2018005256A (en) | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect. | |
| AU2018253620A1 (en) | Injectable botulinum toxin formulations | |
| MX2010002392A (en) | Improved brimonidine compositions for treating erythema. | |
| EA201490512A1 (en) | COMPOSITIONS CONTAINING CULTIVATED IN ANAEROBIC CONDITIONS HUMAN INTESTINE MICROBIOT | |
| GB201101665D0 (en) | Immunogenic compositions | |
| NI201200179A (en) | TREATMENT METHODS AGAINST PANCREATIC CANCER | |
| RU2013108248A (en) | IMMUNOGENOUS ANTI-INFLAMMATORY COMPOSITIONS | |
| NO20091810L (en) | Compositions, sets and applications for protecting the skin against pathogenic microorganisms | |
| NZ602675A (en) | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | |
| PH12020550821A1 (en) | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration | |
| BR112014031394A2 (en) | compositions and methods for transmucosal absorption | |
| ATE395905T1 (en) | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SOLID DISPERSIONS FOR THE TREATMENT OF CANCER | |
| MX2011010050A (en) | Compositions for stimulation of mammalian innate immune resistance to pathogens. | |
| WO2010048087A3 (en) | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone | |
| MX2020005621A (en) | Fatty acid derivatives for treating non-alcoholic steatohepatitis. | |
| MX2019009227A (en) | Methods for treating cancer using hsp90 inhibitors. | |
| AU2010300611A8 (en) | Hematopoietic stem cells for use in the treatment of a kidney injury | |
| BR112013020586A2 (en) | USE OF UMBILICAL CORD TISSUE DERIVED CELLS | |
| MX2011005092A (en) | Octenidine composition. | |
| RU2013132566A (en) | THERAPEUTIC AGAINST HERNIASIS | |
| MX2021011230A (en) | Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases. | |
| NZ601559A (en) | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies | |
| AR112166A1 (en) | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATITIS B | |
| MY197917A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 OCT 2014 BY CPA GLOBAL Effective date: 20140807 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 OCT 2017 BY CPA GLOBAL Effective date: 20140903 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 OCT 2018 BY CPA GLOBAL Effective date: 20170929 |
|
| LAPS | Patent lapsed |